EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.
In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.
Related News
June 11, 2026
Press Releases
Patrick Daugherty Appointed to SEC Investor Advisory Committee
Foley & Lardner LLP partner Patrick Daugherty has been appointed by the Securities and Exchange Commission to its statutory Investor Advisory Committee, which convenes publicly with SEC leadership and other experts several times a year.
June 9, 2026
Press Releases
Foley Expands Employee Benefits and Executive Compensation Capabilities in Chicago with Addition of Three Attorneys
Foley & Lardner LLP announced today the addition of partners Melissa McGrory and Teresa Napoli and associate Madeline Clasen to its Chicago office. Joining from Sidley Austin LLP, the team further strengthens Foley’s national Employee Benefits & Executive Compensation Practice and enhances the firm’s capabilities in its Health Care & Life Sciences, Manufacturing, and Innovative Technology Sectors.
June 4, 2026
Press Releases
Foley Achieves Top Rankings in Chambers USA 2026
Foley & Lardner LLP is proud to once again be recognized by Chambers & Partners as one of the leading law firms in the country in the 2025 edition of Chambers USA: America’s Leading Lawyers for Business.